ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 525 • 2013 ACR/ARHP Annual Meeting

    Evidence For Enhanced Induction Of Unfolded Protein Response Target Genes In Peripheral Blood Mononuclear Cells From Spondyloarthritis Patients

    Grace Kwon1, Eva Yang1, Keith A. Sikora1, Hemalatha Srinivasalu2, Gerlinde Layh-Schmitt1 and Robert A. Colbert3, 1NIAMS NIH, Bethesda, MD, 2Rheumatology, NIAMS NIH, Bethesda, MD, 3NIAMS/NIH, Bethesda, MD

    Background/Purpose: Spondyloarthritis (SpA) is an immune-mediated inflammatory disease strongly associated with HLA-B27 (B27). In a transgenic rat model where B27 causes SpA-like disease, CD8 T…
  • Abstract Number: 526 • 2013 ACR/ARHP Annual Meeting

    Endochondral Bone Formation and Advanced Enthesitis Are Key Features Of Proteoglycan Induced Spondylitis Mouse Model Of Ankylosing Spondylitis

    Gethin P Thomas1, Hsu-Wen Tseng2, Allison Pettit3,4, Tibor T. Glant5, Allan McRae2 and Matthew A. Brown6, 1Translational Reserch Institute, University of Queensland Diamantina Institute, Woolloongabba, Australia, 2University of Queensland Diamantina Institute, Woolloongabba, Australia, 3Mater Research, Woolloongabba, Australia, 4University of Queensland Centre for Clinical Research, Herston, Australia, 5Orthopedic Surgery, Rush University Medical Center, Chicago, IL, 6University of Queensland Diamantina Institute, Brisbane, Australia

    Background/Purpose: Transition from an initial inflammatory phase to the disabling osteoproliferative phase in ankylosing spondylitis (AS) is very poorly understood. Elucidation of the mechanisms underlying…
  • Abstract Number: 527 • 2013 ACR/ARHP Annual Meeting

    Presence Of Gastrointestinal Symptoms and Autoantibodies In Patients With Spondyloarthritis In A Colombian Population

    Consuelo Romero-Sanchez1,2,3, Wilson Bautista-Molano1,4, Diana M Munoz C1, Viviana Parra I1, Alejandro Escobar1, Carlos Martínez5, Ferney Garcia5, Daniel Herrera6, Sebastían Segura1, Juliette De Ávila3, Ana MAría Mesa1, Haroldo Juliao7, John Londono1 and Rafael Valle-Oñate8,9, 1Rheumatology, Spondyloarthropathy Group, Rheumatology Department, Hospital Militar Central/Universidad de La Sabana, Bogotá, Colombia, 2Rheumatology, Universidad Militar Nueva Granada, Bogotá, Colombia, 3School of Dentistry, UIBO Institute (Oral Basic Research Unit),School of Dentistry, Universidad El Bosque, Bogotá, Colombia, 4Universidad Militar Nueva Granada, Bogotá, Colombia, 5Coloproctology, Coloproctology Deparment, Hospital Militar Central, Bogotá, Colombia, 6Genetic, Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia, 7Gastroenterology, Gastroenterology Deparment, Hospital Militar Central, Bogotá, Colombia, 8Spondyloarthritis Group. Rheumatology Department. Hospital Militar Central/Universidad de La Sabana. Bogotá. Colombia, Bogotá, Colombia, 9Rheumatology, Faculty of Medicine, Universidad Militar Nueva Granada, Bogotá, Colombia

    Background/Purpose: The frequency of gastrointestinal (GI) involvement in spondyloarthritis (SpA) ranges from 21% to 30% and 5% to 10% are associated with inflammatory bowel disease…
  • Abstract Number: 528 • 2013 ACR/ARHP Annual Meeting

    Upregulated Th17 and Innate Pathways Are More Characteristic Of The Skin Than The Synovium In Psoriatic Arthritis

    Jennifer Belasco1, Hiroshi Mitsui1, Mayte Suarez-Farinas1, James S. Louie2, N. Wei3, Nicholas Gulati1 and James G. Krueger1, 1Krueger Laboratory, The Rockefeller University, New York, NY, 2Rheumatology, UCLA School of Medicine, Los Angeles, CA, 3Arthritis Treatment Center, Frederick, MD

    Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease associated with psoriasis. There is little understanding of the relative levels of cytokines and chemokines between…
  • Abstract Number: 529 • 2013 ACR/ARHP Annual Meeting

    Ankylosing Spondylitis and Dysfunctional Dkk

    Rajbir Gulati1, Maripat Corr2, Michael H. Weisman3 and David Hallegua4, 1Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, 2Medicine, Univ of California-San Diego, La Jolla, CA, 3Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 4Medicine, Cedars-Sinai/UCLA, Beverly Hills, CA

    Background/Purpose: Ankylosing Spondylitis (AS) is characterized by inflammation of the spine and entheses followed by formation of syndesmophytes. Wnt pathway is a regulator of bone…
  • Abstract Number: 530 • 2013 ACR/ARHP Annual Meeting

    Pattern Recognition Receptor Stimulated Cytokine Expression By Spondyloarthritis Patient Macrophages

    Yi-Ping Liu1, Ashley Bomkamp2, Jens Eickhoff3, Jack Schneck2, Mike Khan4 and Judith Smith5, 1Department of Pediatrics, University of Wisconsin-Madison, Madison, WI, 2University of Wisconsin-Madison, Madison, WI, 3Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, 4Cellular and Molecular Pathology, University of Wisconsin-Madison, Madison, WI, 5Pediatrics, University of Wisconsin-Madison, Madison, WI

    Background/Purpose: Spondyloarthritis (SpA) encompasses a group of chronic inflammatory conditions involving axial arthritis that includes ankylosing spondylitis (AS). GWAS studies in AS have implicated multiple…
  • Abstract Number: 532 • 2013 ACR/ARHP Annual Meeting

    Role Of Baseline C-Reactive Protein In Response To Infliximab Plus Naproxen Vs Naproxen Alone In Patients With Axial Spondyloarthritis

    J Sieper1, M Rudwaleit1, J Lenaerts2, J Wollenhaupt3, L Myasoutova4, S Park5, Y Song6, R Yao7, M Govoni8, D Chitkara9 and N Vastesaeger10, 1University Clinic Benjamin Franklin, Berlin, Germany, 2Practice Rheumatology, Hasselt, Belgium, 3Schön-Klinik, Hamburg, Germany, 4Kazan State Medical University, Kazan, Russia, 5Catholic University of Korea, Seoul, South Korea, 6Seoul National University, Seoul, South Korea, 7Merck & Co., Inc., Whitehouse Station, NJ, 8MSD Italy, Rome, Italy, 9Merck Sharp & Dohme, Kenilworth, NJ, 10Merck Sharp & Dohme, Brussels, Belgium

    Background/Purpose: Baseline inflammation has been shown to influence response to tumor necrosis factor alpha antagonist treatment in patients with axial spondyloarthritis (SpA). This study evaluated…
  • Abstract Number: 535 • 2013 ACR/ARHP Annual Meeting

    Death Receptor 3 Increases Region-Specific, Osteoblast-Dependent Aberrant New Bone Formation In The Axial Skeleton Of Mice In a Spontaneous Model Of Ankylosing Enthesopathy

    Fraser L. Collins1, Jessica O Williams2, Anja C. Bloom1, Michael D. Stone3, Ernest Choy1, Edward C. Wang4 and Anwen S. Williams5, 1Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, 2Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom, 3University Hospital Llandough, Cardiff & Vale University Health Board, Cardiff, United Kingdom, 4Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, 5Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom

    Background/Purpose: Clinical management of localised bone formation and joint ankylosis constitute major challenges in patients with seronegative inflammatory spondyloarthropathies (SpAs).  Whether TNF receptor superfamily members,…
  • Abstract Number: 536 • 2013 ACR/ARHP Annual Meeting

    Membrane-Bound TNF Drives Axial and Peripheral Inflammation and Pathologic New Bone Formation

    Leonie M. van Duivenvoorde1, Melissa N. van Tok1 and Dominique L. Baeten2, 1Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: The morbidity of spondyloarthritis (SpA) is determined not only by inflammation but also by structural damage, in particular osteoproliferation leading to joint ankylosis. The…
  • Abstract Number: 537 • 2013 ACR/ARHP Annual Meeting

    Investigating a Novel Locus For Psoriatic Arthritis

    Ashley Budu-Aggrey1,2, John Bowes1, Pauline Ho1,3, James Bluett1, Harry Hébert1,4, Helena Marzo-Ortega5, Ann W. Morgan6, Matthew A. Brown7, Ross McManus8, Neil McHugh9, Oliver FitzGerald10, Ian N. Bruce2,11,12 and Anne Barton1,2, 1Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 2NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, 3NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, 4The Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 5LMBRU, Chapel Allerton Hospital, and University of Leeds, Leeds, United Kingdom, 6NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 7Human Genetics Group, The University of Queensland Diamantina Insititute, Brisbane, Australia, 8Department of Clinical Medicine, Institute of Molecular Medicine, Trinity College Dublin, Ireland, Dublin, Ireland, 9Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 10Department of Rheumatology, St.Vincent's University Hospital, Dublin, Ireland, 11Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 12Kellgren Centre for Rheumatology, Central Manchester University Hospitals Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) is a complex genetic disorder with a prevalence of up to 1% in the general population. The association of PsA with…
  • Abstract Number: 538 • 2013 ACR/ARHP Annual Meeting

    Ankylosing Spondylitis Associated Endoplasmic Reticulum Aminopeptidase 1 Variants Alter The Unfolded Protein Response

    Nigil Haroon1,2,3 and Zhenbo Zhang3, 1Rheumatology, University Health Network, Toronto, ON, Canada, 2Medicine, Rheumatology, University of Toronto, Toronto, ON, Canada, 3Toronto Western Research Institute, Toronto, ON, Canada

    Background/Purpose: Endoplasmic reticulum aminopeptidase 1 (ERAP1) has recently been identified to be strongly associated with HLA-B27 positive AS. We have shown that ERAP1 variants cause…
  • Abstract Number: 540 • 2013 ACR/ARHP Annual Meeting

    Exploration Of a Novel Therapeutic Target In a Murine Model Of Systemic Lupus Erythematosus: Targeting Sphingosine-1-Phosphate (S1P) Receptors

    Christopher Tracy1, Jess Edison2, S. Frattalone2 and C. Moratz3, 1Internal Medicine-Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, 2Department of Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, 3Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, MD

    Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by symptomatic flares that often result in terminal organ failure.   The pathogenesis is characterized by…
  • Abstract Number: 541 • 2013 ACR/ARHP Annual Meeting

    An Essential Role For Caspase-1 In The Induction Of Murine Lupus and Its Associated Vascular Damage

    J. Michelle Kahlenberg1, Srilakshmi Yalavarthi2, Wenpu Zhao2, Jeffrey Hodgin3, Tamra J. Reed4, Noriko M. Tsuji5 and Mariana J. Kaplan6, 1Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2University of Michigan Rheumatology, Ann Arbor, MI, 3Department of Pathology, University of Michigan, Ann Arbor, MI, 4Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, 53Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan, 6Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune syndrome associated with organ damage and an elevated risk of cardiovascular disease (CVD) resulting from activation…
  • Abstract Number: 501 • 2013 ACR/ARHP Annual Meeting

    A Randomized Placebo-Controlled Phase 2 Study To Evaluate Efficacy, Safety and Tolerability Of Two Secukinumab Loading Dose Regimens In Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate

    Silvano Adami1, André Beaulieu2, Proton Rahman3, Bruno Seriolo4, Janet S. Lee5, Gerhard Krammer6, Brian Porter5, Anuradha Thulasiraman6 and Hanno B. Richards7, 1Rheumatology Department, University of Verona, Verona, Italy, 2Faculty of Medicine, Laval University, Quebec, QC, Canada, 3Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 4Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, 5Novartis Pharma AG, East Hanover, NJ, 6Novartis Pharma AG, Basel, Switzerland, 7Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland

    A Randomized Placebo-Controlled Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of Two Secukinumab Loading Dose Regimens in Subjects with Active Rheumatoid Arthritis Despite…
  • Abstract Number: 502 • 2013 ACR/ARHP Annual Meeting

    Early Introduction Of Biologic Treatment Is An Important Predictor Of Sustained Favorable Outcome Including Clinical Remission In Early Arthritis But Not Of Sustained Favorable Outcome On Structure and Function Only: Results From The Espoir Cohort

    Cécile Gaujoux-Viala1, Laure Gossec2, Maxime Dougados3, Francis Guillemin4 and Bruno Fautrel5, 1EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, 2Rheumatology, Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France, 3Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 4CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, 5Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France

    Background/Purpose: The relevant elements to evaluate health states in RA should include remission, good functional ability and structural stability [1]. The concept of favorable outcome…
  • « Previous Page
  • 1
  • …
  • 2212
  • 2213
  • 2214
  • 2215
  • 2216
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology